Being a world leader in melanoma research, MIA participates in, and presents projects and discoveries, at international skin cancer and oncology conferences.

8 April 2022

Molecular analysis finds excision margin width predictive of recurrence in acral melanoma

Grace H. Attrill, Teresa A. Bailey, Trina Lum, Jordan W. Conway, Georgina V. Long, James S. Wilmott, Richard A. Scolyer

This study aims to determine whether molecular markers can detect molecularly abnormal but histologically normal cells beyond the tumor margin, and whether such cells are associated with recurrence in acral melanoma.

16 Sept 2021

1042P: Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts) (PDF)

Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, Claudia Trojaniello, Florentia Dimitriou, Clara Allayous, Camille Gerard, Lisa Zimmer, Serigne Lo, Olivier Michielin, Celeste Lebbe, Joanna Mangana, Paolo Ascierto, Douglas B. Johnson, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

The AIMS of this study are:
1. To determine the efficacy (objective response rare [ORR], PFS and OS) and safety of PD1 vs IPI+PD1 after BRAF/MEKi.
2. To identify the subgroup of patients with >3 years OS with PD1+/-IPI after BRAF/MEKi.

16 Sept 2021

Efficacy of checkpoint inhibitors in acral melanoma (PDF)

Prachi Bhave, Tasnia Ahmed, Alexander Shoushtari, Anne Zaremba, Judith Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojaniello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Anna Stansfeld, Celeste Lebbe, Julia Katharina Schwarze, Meghan Mooradian, Matteo S Carlino

A study to examine the efficacy of combination checkpoint inhibitors (CPIs) in acral melanoma (AM) compared to single agent CPI, and determine if primary AM site influences patient outcomes.

Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients (PDF)

Ines Pires da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille L. Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen K. Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

Research from MIA’s Medical Oncologist Dr Ines Silva and her team focussed on patients whose disease progressed after first being treated with combination immunotherapy – drugs that stimulate immune cells to fight cancer. Although around half of these patients are still alive five years after starting treatment, the majority of patients will progress and may require further treatment.

IL 6 blockade for prophylaxis and management of immune related adverse events in cancer immunotherapy (PDF)

Florentia Dimitriou, Sabrina Hogan, Phil F. Cheng, Reinhard Dummer, Alexander M. Menzies, Georgina V. Long

Treatment of melanoma with immunotherapy can be lifesaving; however, it can also be complicated by significant side effects as the activated immune system cells may attack healthy cells as well. Immune cells communicate by producing small proteins, called ‘cytokines’, which co-ordinate the body’s response against inflammation. Medical Oncologist Dr Florentia Dimitriou and colleagues identified a cytokine, known as IL-6, which is increased in many inflammatory conditions.

Efficacy of Adjuvant Radiotherapy in Recurrent Melanoma after Adjuvant Immunotherapy (PDF)

Prachi Bhave, Angela Hong, Rebecca Johnson, Alexander M Menzies, Georgina V Long, Joanna Mangana, Douglas B Johnson, Zeynep Eroglu, Ozgecan Dulgar, Hui-Ling Yeoh, Andrew M Haydon, Georg Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kahler, Axel Hauschild, Wei Wang, Matteo S Carlino

In an era where immunotherapy is now often given to reduce recurrence after surgery, Medical Oncologist Dr Prachi Bhave and colleagues at MIA investigated whether adjuvant radiotherapy is still effective in reducing melanoma recurrence. The study found that radiotherapy significantly reduced the risk of melanoma returning in nearby lymph nodes, and therefore continues to have a role in some patients whose melanoma has returned despite receiving immunotherapy after surgery.

Management of resected stage III/IV melanoma with adjuvant immunotherapy (PDF)

Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Weppler, Geoffrey David Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Mark Haydon, Matteo S. Carlino, Shahneen Kaur Sandhu, Georgina V. Long, Alexander M. Menzies

Immunotherapy after surgery for Stage III melanoma has become the standard treatment approach. This research aimed to understand who is being treated with immunotherapy across Australia, how effective the treatment was, and the variety of treatment options that are implemented if the melanoma recurs.

Poster title